Cytek Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
Cytek Biosciences, Inc. filed this Current Report on Form 8-K under Item 5.07 to report the results of its 2023 annual meeting of stockholders, held on June 14, 2023. The filing does not present quarterly or annual operating results.
- Common stock outstanding as of the April 17, 2023 record date: 135,664,817 shares.
- Shares represented at the meeting: 85,215,971, or approximately 63% of shares entitled to vote.
- Trading symbol: CTKB on the Nasdaq Global Select Market.
Financial Metrics, Liquidity, and Capital Structure
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes and Meeting Results
- Class II directors elected: Jack Ball, Vera Imper, Ph.D., and Ming Yan, Ph.D. Each will serve until the 2026 annual meeting or until a successor is elected and qualified.
- Executive compensation: Stockholders approved, on an advisory basis, the compensation paid to named executive officers for the year ended December 31, 2022, with 57,420,396 votes for, 1,390,622 against, and 800,413 abstentions.
- Say-on-pay frequency: Stockholders approved, on an advisory basis, holding future executive compensation votes every one year, with 58,649,562 votes for the one-year frequency.
- Independent auditor: Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 84,894,550 votes for, 11,239 against, and 310,182 abstentions.
- Broker non-votes totaled 25,604,540 for each director election, the executive compensation vote, and the compensation-frequency vote; no broker non-votes were reported for auditor ratification.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, business outlook, risk disclosures, contingencies, or unusual operating items. The principal governance matters were approved, including the annual say-on-pay voting frequency and auditor ratification.
Investor Verification Checklist
- Verify the elected Class II directors and their terms through subsequent proxy or governance disclosures.
- Confirm the company’s implementation of annual advisory votes on executive compensation.
- Review subsequent filings for any developments involving Deloitte & Touche LLP or the company’s 2023 financial results.
- Note that the filing was signed on June 20, 2023, although the annual meeting occurred on June 14, 2023.